Novel functional single nucleotide polymorphisms in the latent transforming growth factor-β binding protein-IL promoter: Effect on latent transforming growth factor- β binding protein- 1L expression level and possible prognostic significance in ovarian cancer

Journal of Molecular Diagnostics

Volumn 8, Issue 3, 2006, Pages 342-350

  Higashi, Tomomi ^a   Kyo, Satoru ^a   Inoue, Masaki ^a   Tanii, Hideji ^a   Saijoh, Kiyofumi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; LUCIFERASE; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1L; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BINDING AFFINITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROGNOSIS; PROMOTER REGION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 33746029430     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2006.050133     Document Type: Article

References (53)

1. Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC: Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Aced Sci USA 1986, 83:2438-2442
2. Shipley GD, Pittelkow MR, Wille Jr JJ, Scott RE, Moses HL: Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986, 46:2068-2071
3. Taipale J, Saharinen J, Keski-Oja J: Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res 1998, 75:87-134
4. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129
5. Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003, 100:8621-8623
6. Miyazono K, Hellman U, Wernstedt C, Heldin CH: Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988, 263:6407-6415
7. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH: Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992, 267:19482-19488
8. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF: Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 1994, 269:6815-6821
9. Taipale J, Miyazono K, Heldin CH, Keski-Oja J: Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994, 124:171-181
10. Saharinen J, Taipale J, Keski-Oja J: Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 1996, 15:245-253
11. Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB: Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem 1996, 271:29891-29896
12. Saharinen J, Keski-Oja J: Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 2000, 11:2691-2704
13. Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin CH: TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell 1990, 61:1051-1061
14. Moren A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K, Heldin CH: Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J Biol Chem 1994, 269:32469-32478
15. Yin W, Smiley E, Germiller J, Mecham RP, Florer JB, Wenstrup RJ, Bonadio J: Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3). J Biol Chem 1995, 270:10147-10160
16. Giltay R, Kostka G, Timpl R: Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins. FEBS Lett 1997, 411:164-168
17. Saharinen J, Taipale J. Monni O, Keski-Oja J: Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J Biol Chem 1998, 273:18459-18469
18. Miyazono K, Olofsson A, Colosetti P, Heldin CH: A role of the latent TGIF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 1991, 10:1091-1101
19. Miyazono K, Thyberg J, Heldin CH: Retention of the transforming growth factor-beta 1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J Biol Chem 1992, 267:5668-5675
20. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin CH, Rifkin DB: Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of enclothelial and smooth muscle cells. J Cell Biol 1993, 120:995-1002
21. Nunes I, Gleizes PE, Metz CN, Rifkin DB: Latent transforming growth factor-beta binding protein domains involved in activation and trans-glutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997, 136:1151-1163
22. Annes JP, Chen Y, Munger JS, Rifkin DIB: Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Bol 2004, 165:723-734
23. Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H: Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res 1993, 53:183-190
24. Koski C, Saharinen J, Keski-Oja J: Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem 1999, 274:32619-32630
25. Olofsson A, Ichijo H, Moren A, ten Dijke P, Miyazono K, Heldin CH: Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extra-cellular matrix. J Biol Chem 1995, 270:31294-31297
26. Higashi T, Sasagawa T, Inoue M, Oka R, Shuangying L, Saijoh K: Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. Jpn J Cancer Res 2001, 92:506-515
27. Lench N, Stanier P, Williamson R: Simple non-invasive method to obtain DNA for gene analysis. Lancet 1988, 1:1356-1358
28. Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 1998, 7:719-724
29. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T: Sp3, but not Sp1, mediates the transcriptional activation of the p21/ WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 1999, 59:4266-4270
30. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, Tanaka M, Inoue M: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 2001, 29:3006-3011
31. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999, 59:5511-557
32. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M: Significance of immunological detection of hurnan telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 2003, 163:859-867
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 54:457-481
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170
35. Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G: Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-promoter. Eur J Immunogenet 2004, 31:15-19
36. Gazzoli I, Kolodner RD: Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 2003, 23:7992-8007
37. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA: Linked common polymorphisms in the gelatinase A promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003, 278:20490-20499
38. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003, 63:812-816
39. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM, Ralston SH: A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001, 107:899-907
40. Zhao L, Chang LS: The human POLD1 gene. Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation. J Biol Chem 1997, 272:4869-4882
41. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook Jr EH, Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005, 65:46-53
42. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61:4143-4154
43. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000, 60:1546-1551
44. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Haruma K, Kajiyama G, Tahara E: The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 1992, 189:1342-1348
45. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S: Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002, 2:35-38
46. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH: Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993, 90:6076-6080
47. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T: Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999, 59:3379-3386
48. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112:1116-1124
49. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis, Proc Natl Acad Sci USA 2003, 100:8430-8435
50. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL: Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 2003, 23:8691-8703
51. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ: TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996, 86:531-542
52. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990, 87:1486-1490
53. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109:1551-1559